Olivier Lantrès | Fieldfisher
Skip to main content
Select location
Professional background

Professional background

Olivier is an expert on regulatory issues in the life sciences and healthcare sectors, in particular concerning medical devices, pharmaceutical and phytopharmaceutical products and cosmetics.

His main area of practice involves matters relating to advertising of pharmaceutical products, relationships with healthcare practitioners, clinical trials, and advising clients in the context of monitoring by the health authorities.

He is a Doctor of Law (magna cum laude) and ranked as a 'Leading Individual' by Legal 500 (2022) as well as Band 1 in Chambers 2022. In addition to this, He is also recognised and ranked by a number of other directories including PLC Which Lawyer, Best Lawyers in France and Décideurs Stratégie Finance Droit.

He was awarded a first prize by the French Healthcare Law Association for his work and also is a member of the professional associations ACIP and AMIPS.

He joined Fieldfisher as a Partner in 2008 after having worked with Price Waterhouse Coopers and Proskauer Rose LLP.

In addition to his native French, he is fluent in English.

 

Awards & recognition

Awards & recognition

Client
We had the pleasure of working with Mila Kovalenko, who exhibits outstanding professionalism and thorough knowledge of her areas of practice.
Chambers & Partners 2022
He has extremely good knowledge of the healthcare sector. He is always available and is very efficient.
The Legal 500 EMEA 2022
Olivier Lantrès has solid experience and excellent knowledge of the health sector and the issues encountered by his clients. He is surrounded by a competent and very responsive team. He is always there and always finds relevant and business-oriented solutions for his clients. Olivier has an activity established at Fieldfisher for many years which allows him to work transversally with the other teams of the firm. He is very responsive and, with his team, produces quality work at ‘fair’ prices.

Authored pieces

All Resources
A digital illustration of a glowing DNA double helix strand made up of colorful light particles, set against a dark background with purple and blue hues.
Life Sciences
Insight

ECJ's landmark ruling on defective products liability: What it means for life sciences manufacturers

30.03.2026
On 26 March 2026, the European Court of Justice (ECJ) issued a significant and precedent-setting judgment reshaping the liability landscape for defective products in the pharmaceutical sector. Although the case concerned a medicinal product (a vaccine), the Court’s reasoning extends in practice to medical device manufacturers, even though the judgment did not explicitly reference devices.
Learn more
Several packs of pills in various shapes and colors are scattered on a surface. The medication is contained in blister packs, with some capsules being half white and half blue, others in different color combinations. The image uses blue and pink lighting.
Life Sciences
Insight

LFSS 2026: What the new Supplementary Contribution means for Pharma

10.03.2026
Learn more
A digital abstract image featuring a glowing blue particle wave flowing through a dark background. Below the wave, a network of interconnected points and lines creates a web-like structure, also illuminated in blue, giving a sense of data transmission and connectivity.
Life Sciences
Press Release

Fieldfisher secures key regulatory victories for Philagro France and Suterra in market access disputes

28.03.2025
Learn more
A modern operating room filled with medical equipment. There's a surgical table in the center, surrounded by monitors, overhead lights, and various machines. The lighting is dim with a bluish hue, giving an ambient atmosphere.
Insight

French judges clarify the notion of medical devices

18.02.2025
Learn more
Insight

The French drug agency today published 33 decisions imposing fines on pharmaceutical companies for alleged non-compliance with the French rules on safety stocks

24.09.2024
In 2021, the French drug agency determined that the stocks of hundreds of specific pharmaceutical products must be maintained by pharmaceutical companies at a level equivalent to 4 months of coverage usual public consumption. In April 2023, the agency checked for the first time whether the pharmaceutical sector was complying with this rule.
Learn more
Lawyers I've worked with
Find a lawyer

What others say…

Client
We had the pleasure of working with Mila Kovalenko, who exhibits outstanding professionalism and thorough knowledge of her areas of practice.
Chambers & Partners 2022
He has extremely good knowledge of the healthcare sector. He is always available and is very efficient.
The Legal 500 EMEA 2022
Olivier Lantrès has solid experience and excellent knowledge of the health sector and the issues encountered by his clients. He is surrounded by a competent and very responsive team. He is always there and always finds relevant and business-oriented solutions for his clients. Olivier has an activity established at Fieldfisher for many years which allows him to work transversally with the other teams of the firm. He is very responsive and, with his team, produces quality work at ‘fair’ prices.